{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"argenx SE"},"Symbol":{"label":"Symbol","value":"ARGX"},"Address":{"label":"Address","value":"WILLEMSTRAAT 5, BREDA, 4811 AH, Netherlands"},"Phone":{"label":"Phone","value":"+31 763030488"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Europe"},"CompanyDescription":{"label":"Company Description","value":"argenx SE is an immunology company. It is engaged in the business of developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. The group has partnered with academic researchers through its Immunology Innovation Program (IIP) and aims to translate immunology breakthroughs into a portfolio of novel antibody-based medicines. argenx developed and is commercializing the neonatal Fc receptor (FcRn) blocker in the U.S., Japan, and the EU. Its product pipeline includes product candidates such as ARGX-117, ARGX-118, ARGX-115, ARGX-116, and others."},"CompanyUrl":{"label":"Company Url","value":"https://www.argenx.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Luc Truyen","title":"Chief Medical Officer"},{"name":"Peter Ulrichts","title":"Chief Scientific Officer"},{"name":"R. Keith Woods","title":"Chief Operating Officer"},{"name":"Tim van Hauwermeiren","title":"Chief Executive Officer &amp; Executive Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}